Novo Nordisk has launched Ozempic, the original semaglutide (GLP-1 RA) therapy, in India. It comes in 0.25 mg, 0.5 mg, and 1 mg doses in a FlexTouch Pen. The weekly prices are ₹2,200 for 0.25 mg, ₹2,542 for 0.5 mg, and ₹2,794 for 1 mg. Ozempic is approved as a first-line treatment for adults with type 2 diabetes, alongside diet and exercise. The World Health Organization recently added semaglutide to its Model List of Essential Medicines, recognizing its health benefits. India faces a big diabetes challenge, with 101 million people living with diabetes and 136 million with prediabetes, according to WHO's 2023-24 data. Vikrant Shrotriya, Managing Director of Novo Nordisk India, said, "Bringing Ozempic to India is a major milestone. Backed by proven clinical excellence & world class quality, reinforced by a robust supply chain, Ozempic offers Indian doctors an effective treatment choice. Our goal is to provide patients an innovative and accessible therapy that offers improved glycaemic control, meaningful weight management and long-term heart and kidney protection – all delivered through a simple, easy-to-use pen device. This once-weekly treatment demonstrates Novo Nordisk’s ongoing commitment to better health outcomes and chronic disease care."